Cytospire was in the spotlight this morning after announcing an oversubscribed Series A to fund a new form of T-cell engager (TCE) for cancer.

For the first time in its 16-year history, Deloitte’s annual report on pharma R&D returns sees obesity replace cancer as the largest driver.

After abandoning an IPO bid last year, Odyssey is trying again, emboldened by recent big-value listings that suggest 2026 could be a bumper year.

Vertex Pharmaceuticals said it has dropped development of an mRNA-based cystic fibrosis therapy, after facing challenges delivering the genetic medicine similar to those that have

The FDA has narrowed its search for a new leader of its Center for Biologics Evaluation and Research to three to four final candidates, according